Pharmaceuticals company Sai Life Science announced Q3FY25 results Revenue from Operations was Rs 439.8 crore for Q3FY25 compared to Rs 383.6 crore in Q3FY24, an increase of 14.6%. EBITDA stood at Rs 124.5 crore for Q3FY25 compared to Rs 104.2 crore in Q3FY24 an increase of 19.5%. PAT stood at Rs 53.9 crore for Q3FY25 compared to Rs 39.6 crore in Q3FY24, an increase of 36.0%. Krishna Kanumuri, Managing Director & CEO, Sai Life Sciences, said: “We are pleased to announce a healthy performance this quarter, driven by strong execution, expanding capacity, and deepening customer relationships. Our integrated CRDMO model continues to differentiate us in the market, enabling us to provide seamless solutions across the drug development lifecycle. The pharmaceutical and biotech industries are increasingly seeking partners with end-to-end capabilities, scientific excellence, and a commitment to speed and efficiency areas where Sai Life Sciences has built a strong competitive edge. The global CRDMO industry presents a tremendous growth opportunity, particularly as large pharmaceutical and biotech companies diversify their supply chains and seek strategic partners beyond China. India is at the forefront of this transformation, with the potential to scale as a global innovation hub. With a robust pipeline of commercial molecules, a growing presence in key global markets, and continuous investments in technology and infrastructure, Sai Life Sciences is well-positioned to capitalize on these industry tailwinds. As we look ahead, we remain focused on strengthening our service offerings, expanding our capabilities into new modalities, and driving operational excellence. Our unwavering commitment to innovation, quality, and customercentricity will continue to propel us forward, delivering sustainable value to all our stakeholders.” Siva Chittor, Chief Financial Officer, Sai Life Sciences, said:” We are delighted to share our Q3 FY25 financial performance, which highlights robust business momentum, operational discipline, and strong customer relationships. Revenue from operations grew to Rs 439.8 crore, up 15% from Rs 383.6 crore in Q3FY24, on account of continued momentum in both our CDMO and CRO businesses. Our EBITDA margin increased to 28.3% in Q3FY25, up from 27.5% in Q3FY24, reflecting improved operating leverage and enhanced productivity. PAT grew to Rs 53.9 crore, compared to Rs 39.6 crore in Q3FY24, highlighting that our operational strategies are delivering results and positioning the company for sustained financial strength. This success is driven by disciplined cost management despite rising employee costs in line with our ongoing investment in talent and organizational growth. Finance costs remained relatively stable at Rs 23.1 crore for Q3FY25, compared to Rs 23.3 crore in the same quarter last year, indicating effective debt management. As of December 2024, the Company had repaid Rs 585.7 crore of debt out of the planned Rs 720.0 crore from the IPO proceeds. The remaining debt was repaid in January, and we expect a reduction in interest costs in the following quarter. We remain focused on investing in digital initiatives, new technologies, and commercial capabilities to fuel future growth. Over the past five years, our strategic investments in talent, technology, and infrastructure have strengthened our position as a leading integrated CRDMO player. These investments are now translating into higher customer retention, an expanding product pipeline, and improving profitability. Looking ahead, we expect sustained growth momentum, supported by a strong order pipeline and ongoing investments in infrastructure and capabilities.” Result PDF